Jason Alter, Ph.D.
Vice President of Marketing for Aureon Laboratories
Dr. Alter graduated from Alfred University with a B.A. in Biology
and History. Subsequently he earned a M.S. degree in Microbiology
from Texas A&M University and his Ph.D. in Molecular Biology
from Binghamton University. Dr. Alter did a postdoctoral fellowship
at Schering Plough Pharmaceuticals examining the cellular location
of fibronectin and collagen 01 (IV) messenger RNAs during intimal
lesion development in a balloon angioplasty model of vascular
smooth muscle cell proliferation. Dr. Alter has worked in a
number of marketing roles for both traditional and non-traditional
life science companies (e.g. IBM). Dr. Alter joined IBM's
newly-formed Life Sciences Division as a Marketing Manager and was
responsible for many of the initial outbound marketing activities
of this business unit. Subsequently, as Manager of Program
Marketing, he and his team were responsible for all outbound
marketing for the IBM Healthcare and Life Sciences team.
John D. Haley, Ph.D.
Senior Research Director, Translational Research OSI
Pharmaceuticals, Inc.
Dr. Haley has over thirty years of experience in biochemical
research in the fields of endocrinology, oncology, signal
transduction and pharmacology, in which he has published over 50
manuscripts. Dr. Haley obtained B.Sc. cum laude in Chemistry
from Tufts University, Medford, MA and a Ph. D. in Molecular
Endocrinology from the Howard Florey Institute for Experimental
Physiology and Medicine, Melbourne University, Australia. He
served as a Research Fellow at the Imperial Cancer Research Fund
(London) and at the Ludwig Institute for Cancer Research (London).
He currently holds the position of Senior Research Director,
Translational Research at OSI Pharmaceuticals, and his group is
focused on drug target pathway identification, validation and
biomarker discovery through a scientific understanding of
epithelial-mesenchymal transition and cancer recurrence.
Joseph Scaduto, M.S., M.B.A.
Assistant Director of Business Development Center for Biotechnology
(CFB), State University of New York at Stony Brook
Mr. Scaduto is the founding Executive Director of the Long Island
Life Sciences Initiative (LILSI). He has accumulated almost 10
years of experience providing business development expertise,
strategic planning services and technology commercialization
guidance to emerging and expanding bioscience companies on Long
Island and throughout New York State. Mr. Scaduto is primarily
responsible for corporate outreach, industry relations and
government affairs activities on behalf of the CFB. He leads
efforts to plan and execute the annual Life Sciences Industry
Summit, while administering several programs meant to facilitate
industry-academic interactions, technology transfer and new company
formation, including BioPartnering Meetings, BioStrategy Sessions
and the Technology Commercialization Clinic (TCC). Mr.
Scaduto serves on the Tenant Selection and Review Committee of the
Long Island High Technology Incubator (UHTI), the Stony Brook
University Software Incubator, and the Stony Brook University
Incubator at Calverton. Prior to joining the CFB, Mr. Scaduto
held a variety of laboratory research and technology management
positions at Stony Brook University, Brookhaven National
Laboratory, Binghamton University, Mount Sinai Graduate School of
Biological Sciences, BioLife Solutions, Inc. and The Collaborative
Group, Ltd.
Daniel B. Yarosh, PhD
Senior Vice President, Basic Science Research Estee
Lauder
Dr. Yarosh, is Senior Vice President, Basic Science Research, and
is responsible for worldwide basic research of the Estee Lauder
companies. Until 2008, he was President and Chairman of the Board,
AGI Dermatics, located in Freeport, Long Island, New York. Dr.
Yarosh received his BA degree in Biology from Macalester College,
St. Paul, Minnesota, in 1976, and his Doctorate in Molecular
Biology from the University of Arizona College of Medicine, Tucson,
Arizona, in 1978. He served as a National Science Foundation Fellow
at Brookhaven National Laboratory, Upton, New York, and then a
Staff Fellow and Cancer Expert at the National Cancer Institute of
the National Institutes of Health, Bethesda, Maryland. In 1985, Dr.
Yarosh founded AGI Dermatics, with an emphasis on the commercial
application of DNA repair. He is the inventor of Dimericine® (T4N5
liposome lotion), which is a liposomal DNA repair enzyme for the
prevention of skin cancer. AGI Dermatics is also an ingredient
supplier to many major worldwide cosmetic and personal care
companies. In 2006 the company launched its own Remergent® brand of
skincare products, including sunscreens and prescription drugs. In
2008, AGI Dermatics was acquired by Estee Lauder Inc. Dr. Yarosh is
the author of more than 100 scientific papers and two dozen
patents, and serves on the Board of the Photomedicine Society. His
book The New Science of Perfect Skin, about skincare technology in
the cosmetic marketplace, was published by Random House in May
2008.